Zobrazeno 1 - 10
of 202
pro vyhledávání: '"Xingya Li"'
Autor:
Ying Cheng, Chunjiao Wu, Lin Wu, Jun Zhao, Yanqiu Zhao, Lulu Chen, Ying Xin, Liang Zhang, Pinhua Pan, Xingya Li, Juan Li, Xiaorong Dong, Ke Tang, Emei Gao, Fei Yu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract This single-arm, multi-center clinical trial aimed to evaluate the safety, tolerability, DLT, recommended dose (RD), preliminary efficacy, and pharmacokinetics (PK) characteristics of lurbinectedin, a selective inhibitor of oncogenic transcr
Externí odkaz:
https://doaj.org/article/aaeda2d4fe5546aaa40b29b0239798e3
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The impact of immune checkpoint inhibitors (ICIs) based treatments on non-small cell lung cancers (NSCLCs) with RET fusions remains poorly understood. Methods We screened patients with RET fusions at the First Affiliated Hospital
Externí odkaz:
https://doaj.org/article/8ea25916d815463c8b5343bf26a27f79
Autor:
Yongfeng Yu, Wen Dong, Yanxia Shi, Rong Wu, Qitao Yu, Feng Ye, Chengzhi Zhou, Xiaorong Dong, Xingya Li, Yongsheng Li, Zhen Li, Lin Wu, Yueyin Pan, Hong Shen, Dehua Wu, Zhongyuan Xu, Jinsheng Wu, Nong Xu, Yanru Qin, Aimin Zang, Jingdong Zhang, Jianya Zhou, Xiaotao Zhang, Yanqiu Zhao, Fugen Li, Huizhen Wang, Qi Liu, Zhenyong Han, Jin Li, Shun Lu
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: MET overexpression represents the most MET aberration in advanced non-small-cell lung cancer (NSCLC). However, except MET exon 14 ( MET ex14) skipping mutation was recognized as a clinical biomarker, the role of MET overexpression as a pr
Externí odkaz:
https://doaj.org/article/8250df8367a343a395e6e10c30dba4a2
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThis retrospective study evaluates the efficacy of camrelizumab combined with anlotinib versus chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) undergoing second-line treatment.MethodsData were sourced from m
Externí odkaz:
https://doaj.org/article/777c5109fd97437f9bd9d587d8ad9f52
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/570562c10b6a4ffc942493101a6f29a0
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundProgrammed cell death ligand 1 (PD-L1) is more readily expressed in ROS proto-oncogene 1 (ROS1) rearranged non-small cell lung cancer (NSCLC) compared to NSCLC cases lacking driver gene mutations. Prior research has established a link betwe
Externí odkaz:
https://doaj.org/article/44ad15ab6e5442ee84668be3d45442c2
Autor:
Likun Chen, Jose David Gomez Rangel, Timucin Cil, Xingya Li, Irfan Cicin, Yihong Shen, Zhihua Liu, Ozgur Ozyilkan, Bondarenko Igor, Jun Chen, Kostiuk Oleksandr, Zhendong Chen, Helong Zhang, Ziyi Fu, Qingfeng Dong, Shuqiang Song, Jin‐Chen Yu, Li Zhang
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 20847-20863 (2023)
Abstract Background BAT1706 is a proposed biosimilar of bevacizumab (Avastin®). We aimed to compare the efficacy and safety of BAT1706 with that of EU‐sourced reference bevacizumab (EU‐bevacizumab) in patients with advanced nonsquamous non‐sma
Externí odkaz:
https://doaj.org/article/81f12a95ae2a40989aaa39d8ab3f0483
Autor:
Siyuan Huang, Linlin Li, Ningning Yan, Huixian Zhang, Qianqian Guo, Sanxing Guo, Di Geng, Xincheng Liu, Xingya Li
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundHighly selective type Ib mesenchymal–epithelial transition gene (MET) tyrosine kinase inhibitors (TKIs) are the standard-of-care (SOC) therapy for previously untreated non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) ski
Externí odkaz:
https://doaj.org/article/2ff5d269d0794cdda1e223c999210bff
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundFurmonertinib is the standard treatment option in the first-line setting for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations in China. However, there are limited real-world data a
Externí odkaz:
https://doaj.org/article/bd730ae7179342549bfe7f0c8f14b9f5
Autor:
Shiqi Mao, Shuo Yang, Xinyu Liu, Xingya Li, Qiming Wang, Yiping Zhang, Jianhua Chen, Yan Wang, Guanghui Gao, Fengying Wu, Tao Jiang, Jiao Zhang, Ying Yang, Xiang Lin, Xiaoyu Zhu, Caicun Zhou, Shengxiang Ren
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-10 (2023)
Abstract Background Non-small cell lung cancer (NSCLC) with HER2 mutation has entered into the era of targeted therapy. However, both anti-HER2 antibody–drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs) showed moderate objective response
Externí odkaz:
https://doaj.org/article/881e6699d1604387a9dfe886cec0c786